Effects of a Standardised Saffron Extract Supplementation on Symptoms Associated With Perimenopause in Healthy Women

L

Liaquat University of Medical & Health Sciences

Status

Enrolling

Conditions

Perimenopausal Disorder

Treatments

Dietary Supplement: Safr'Inside supplement (Activ'Inside, SAS)
Other: Plcebo

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06227858
LUMHS/REC/-221

Details and patient eligibility

About

The aim of the present study is to assess the effects of a normalised saffron extract supplementation, which is an extract of the flower Crocus sativus, on perimenopausal symptoms.

Full description

After being informed about the study protocol aim and potential risks, healthy volunteer woman (walk-in outpatients) will undergo a pre-screening to determine eligibility for study entry. At the visit 1, patients who meet the pre-screening criteria will undergo a second screening to confirm their eligibility based on inclusion and exclusion criteria. After signing the inform consent form, patient who meet eligibility criteria will be randomised in a double-blind manner (participants and investigators) in a 1:1 ratio to saffron extract supplementation (15mg, twice daily) or matched placebo (twice daily) for a period of 3-months (12 weeks).

Enrollment

104 estimated patients

Sex

Female

Ages

40 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Biological Female which identify themselves as Women
  • Aged ≥ 40 years
  • Irregular menstrual cycle for at least 3 months
  • Presenting typical symptoms of perimenopause with GCS score over 20
  • BMI range between 18-35 kg/m2
  • Healthy woman

Exclusion criteria

  • Less than 40 years old
  • Pregnant
  • Diagnosed with diseases related to reproductive system such as PCOS or endometriosis
  • Taking anti-depressant medication or sleeping pills
  • Taking hormonal replacement therapy (HRT)
  • Taking conventional drug treatment or dietary supplementation
  • Having medical history or medical/surgical event in the last 6 months, or has been treated for cancer or any other ongoing treatment for the past 3 months,
  • Current and/or past history of hyper/hypotension, CVD, diabetes, autoimmune diseases, musculoskeletal disorder or endocrine or immunocompromised or neurological or psychological disorders,
  • Being medicated for these conditions,
  • History of allergic reactions to saffron intake,
  • Decisionally challenged subjects or unable to comply to the study
  • Any conditions that could contraindicates the use of saffron
  • Currently smoking or ceased smoking in the past 3 months

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Quadruple Blind

104 participants in 2 patient groups, including a placebo group

Saffron extract supplementation (15mg, twice daily)
Experimental group
Description:
The experimental group will take a single capsule containing: 15mg of of saffron extract (stigma of the flower Crocus sativus), 340mg of Maltodextrin, encapsulated in hydroxypropyl methyl cellulose (HPMC), twice daily (one morning and one evening after the meal).
Treatment:
Dietary Supplement: Safr'Inside supplement (Activ'Inside, SAS)
Control group
Placebo Comparator group
Description:
The Control group will take a single placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron) twice daily (one morning and one evening after the meal).
Treatment:
Other: Plcebo

Trial contacts and locations

1

Loading...

Central trial contact

Dr. Amjad Khan, DPhil

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems